Trius Gets FDA Clarity
Trius Therapeutics, the San Diego-based developer of antibiotics, said today it has agreed with the FDA on a special protocol assessment that establishes the design for a pivotal clinical trial. The clarity from the FDA is vital to Trius and its lead drug candidate, torezolid phosphate. The company postponed its IPO plans in March after it learned of new FDA guidelines that altered its plans for a pivotal antibiotic study. Trius didn’t say in today’s statement what its next move is on the IPO front.